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The most complete picture of the impact of tumor development
on bone marrow cells migration and distribution required to
better understanding the process of forming a tumor
microenvironment.
The objective of the present study was to investigate the
influence of growth and progression of melanoma B16F10 on
unfractionated bone marrow cells (BMCs) distribution.
Materials and Methods: There were two groups of mice in this
study: healthy + intravenously transplantation BMCs (n = 5),
B16F10 + intravenously transplantation BMCs (3 days later tumor
inoculation) (n = 5). Whole bonemarrowwas harvested frommale
C57Bl6 mice and transplanted into female recipient C57BL6 mice
bearing melanoma B16F10 or healthy female mice. After 7 and
14 days of cell transplantation (10, 17 days after tumor inocula-
tion, respectively), the animals were sacrificed by cervical disloca-
tion. The blood, tumor, lymph nodes, sentinel lymph nodes
(regional lymph nodes), lung, liver, spleen, bone marrow, brain,
heart from each animal was immediately excised and processed
for qPCR analysis. To further validated PCR measurements was
performed fluorescence microscopy section of bone marrow of
mice bearing melanoma B16F10 to detection Hoechst 33342
labeled transplanted cells.
Results: In 10 days after tumor inoculation both healthy mice
and mice bearing melanoma B16F10, 80–90% of total detected
cells were identified in spleen and bone marrow. Accumulation
of BMCs was mainly observed in spleen of healthy animals (mean
4424/100,000, standard deviation 1005/100,000), whereas spleen of
mice bearing melanoma B16F10 contained significantly smaller
number of cells (mean 947/100,000, standard deviation
203/100,000) (p < 0.001).
Accumulation of BMCs was observed mainly in the bone mar-
row of mice bearing melanoma B16F10 (mean 5554/100,000, stan-
dard deviation 925/100,000), whereas bone marrow of healthy
mice contained significantly lower number of transplanted BMCs
(mean 2193/100,000, standard deviation 921/100,000) (p < 0.001).
Tumor contained a small number of Y-positive BMCs (mean
135/100,000, standard deviation 13/100,000). Significant differ-
ences in the quantitative distribution of BMCs in other examined
organs were not found.
In 14 days after cells transplantation(17 days after tumor inoc-
ulation) 80% of cells was detected in lymph nodes of healthy mice
(mean 3190/100,000, standard deviation 756/100,000). 10%
Y-positive BMCs into bloodstream of healthymice was also found,
whereas transplanted BMCs were not found in the lymph nodes
and bloodstream of mice bearing tumor. At this time it was
revealed that bone marrow of mice bearing melanoma B16F10
contained BMCs in 50 times greater than in bone marrow of
healthy mice (mean 2309/100,000, standard deviation
695/100,000 and mean 42/100,000, standard deviation 10/100,000
respectively). Tumor of mice bearing melanoma B16 contained
large amount of Y-positive BMCs (mean 569/100,000, standard
deviation 262/100,000). The liver, spleen, lung and heart did not
contain significant amount of Y positive BMCs.
Fluorescence microscopy provided clear evidence of Hoechst
33,342 labeled transplanted cells migrated to the bone marrow
of mice bearing melanoma B16F10 and further validated our
PCR measurements. Only a small number of BMCs migrated and
engrafted to bone marrow of healthy mice, while bone marrow
of mice with melanoma B16F10 contain significant number of
transplanted BMCs 10 and 17 days after BMCs administration.
Conclusion: Thus, it is shown that melanoma B16F10 regulate
distribution of BMCs with a preferred orientation in the host bone
marrow.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.100
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Adenoma and adenocarcinoma of the stomach are related to
precancerous states and considered as successive stages of disre-
generatory process proceeding against a background of chronic
inflammation relying on cytokine-producing function of immune
cells.
Objective: Evaluation of cytokine-producing function of blood
immunocompetent cells under the influence on polyclonal
activators in patients with adenoma and adenocarcinoma of the
stomach.
Materials and Methods: Peripheral blood of 56 patients includ-
ing 32 patients with adenomas and chronic atrophic gastritis and
24 patients with adenocarcinoma of the stomach was taken
before surgery and biopsy. Peripheral blood of 30 healthy individ-
uals was used as a control. To assess the status of the gastric
mucosa, concentrations of pepsinogen I and pepsinogen II were
determined in addition to instrumental methods. Cytokine-
producing capacity of blood cells was determined using a poly-
clonal activator (PA) composed of PHA (4 lg/ml), conA (4 lg/ml)
and LPS (2 lg/ml). Concentrations of the following cytokines:
IL-1b, IL- 1Ra, TNFa, IL-2, IL-6, IL-8, IL-10, IL-17, IL-18, MCP-1, VEGF
and IFNc in the supernatant of blood cells were measured with
enzyme-linked immunosorbent assay (ELISA). The index of
polyclonal activators unfluence (IPAI) on cytokine production
was calculated: IPAI = A/B, where A is cytokine production
induced by PA, B-spontaneous cytokine production level.
Results: In patients with stomach adenomas, serum concen-
tration of pepsinogen I and the pepsinogen I/pepsinogen II ratio
were significantly lower compared with healthy individuals
indicating the development of adenoma combined with gastric
mucosa atrophy. Pepsinogen I concentration was in inverse corre-
lation with the percentage of Ki-67 positive epithelial cells, which
was also in inverse correlation with IPAI of IFNc possessing
antiproliferative action. In patients with stomach adenomas,the
increased IPAI of receptor antagonist IL-1compared with the con-
trol was revealed, that could lead to inflammation incomplete-
ness and its torpid course. In conjunction with IPAI, increase in
IL-18 level stimulates proliferative processes and contributes to
disregeneratory changes in the stomach epithelium. Direct corre-
lation between the ability of blood cells to the produce IL-1Ra
under the PA influence and the number of metastases in the
regional lymph nodes as well as reverse correlation between IPAI
of IL-2 and the number of low differentiated cells in the tumor
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were observed. In patient with stomach adenomas, degree of
atrophy increases as the pepsinogen I/pepsinogen II ratio
decreases, the ability of immune cells to produce IL-18 under
the influence of PA stimulates proliferation of cells, including
atypical.
Conclusion: Findings suggest the ability of blood cells to pro-
duce TNFa, IL-18 and IFNc under the influence of polyclonal acti-
vators was higher in patients with stomach adenomas than in
patients with stomach adenocarcinomas. In patients with adeno-
carcinomas the decline in the production of cytokines with both
the proliferative and antiproliferative effects indicates radical
changes in the cytokine-producing capability of immunocompe-
tent cells when malignant neoplasm became mature.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.101
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Background: Tumour-associated macrophages (TAM) derived
from peripheral blood monocytes are a key immune regulatory
component of tumour microenvironment (Qian, Pollard, 2010).
Advanced clinically applicable strategy for TAM targeting is their
functional reprogramming (Wynn et al., 2013). Monocytes/
macrophages are heterogeneous and versatile cells. Two major
macrophage subpopulations with different functions which rep-
resent extreme of a continuum in a universe of activation states,
including classically activated/inflammatory (M1) and alterna-
tively activated/regenerative (M2) macrophages, have long been
recognized (Zhou et al., 2014). CD68 and CD163 are the general
markers of M1 and M2 subsets respectively (Hoene et al., 2015,
Tedesco et al., 2014). However, there are different markers
expressed on surface of monocytes/macrophages that reflected
some special functional activities of these cells. Thus, expression
of CD119(IFN-cR) or CD124(IL-4R) reflects the predisposition to M1
or M2-polarisation by suitable cytokines IFN-c and IL-4 (Tedesco
et al., 2014). The pro-inflammatory marker CD282 (TLR2) is asso-
ciated with antibacterial function. Anti-inflammatory CD36+ cells
take part in scavenging of apoptotic remains and inducing IL-10
production. Although monocytes/macrophages could undergo
their phenotypically/functionally dynamic switch in response to
the microenvironment signals there is some predisposition of
their status in peripheral blood to polarization in tissues. Modula-
tion of monocyte peripheral status before their infiltration is an
attractive target for cancer therapeutic approaches.
The aim is to study phenotypic subsets of peripheral blood
monocytes in breast and gastric cancer patients.
Materials and methods: 8 breast cancer and 8 gastric cancer
patients T1N0-3M0 treated in Tomsk Cancer Institute were
enrolled in investigation. The diagnosis was histologically veri-
fied. Phenotypic features were assessed by flow cytometry using
mAb CD119(IFN-cRa), CD124(IL-4R), CD282 (TLR2), CD36, CD68,
CD163 (BD Pharmingen) before treatment and in 5 days after sur-
gery of tumour.
Results: We found that amounts of monocytes expressing
main surface markers of M-1 or M2-type activation in peripheral
blood in cancer patients wasn’t large: CD68+ and CD163+ cells
were 4.18 ± 3.41% and 7.64 ± 3.75% of whole pool of monocytes
respectively. This finding supports the fact that in general
M1/M2-polarization of monocytes/macrophages occurs in local
tissues by specific micro- environmental conditions [Ambarus
et al., 2012, Zhou et al., 2014]. But high levels of CD119(IFN-cR)+
monocytic cells (87.36 ± 12.08%) in peripheral blood showed that
predisposition to M1-polarization of circulating monocytes exists
in cancer patients, because it’s known IFN-c significantly
increased the fraction of surface CD68 – expressing cells and
down-regulated expression of the M2 markers in vitro [Tedesco
et al., 2014]. Expression of CD124 (IL-4R) was detected only in
26.81 ± 8.11% of monocytes in cancer patients. The subset of
pro-inflammatory CD282+ (TLR2) circulating monocytes
amounted 64.38 ± 9.47% of total count of monocytic cells. Anti-
inflammatory CD36+ monocytes were 35.66 ± 7.00%. It is notewor-
thy this subset was 48.43 ± 8.13% in breast cancer patients and
only 22.88 ± 9.86% in gastric cancer patients (p < 0.05).
On the 5-th day after surgery, we detected decrease in CD282+
cells from 80.90 ± 8.55% to 38.70 ± 9.47% of total monocytes count
in breast cancer patients (p < 0.05). Another noticeable feature of
monocytes pool after operation was increasing of anti-
inflammatory CD36+monocytes as in breast (1.69-fold) and
gastric (1.97 fold) cancer patients.
Conclusion: There were a small accounts of M1 (CD68+) or M2
(CD163+) polarized monocytes in peripheral blood in breast and
gastric cancer patients. INF-c(CD119)+ and CD282(TLR2)+ pro-
inflammatory subsets were dominated in cancer patients. The
high levels of CD36+monocytes was the feature of breast cancer
patients as compared with gastric cancer ones. Surgery removal
of tumour was associated with increasing of CD36+ monocytes
in both breast and gastric cancer and with decreasing of CD282
(TLR2)+ monocytes in breast cancer.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.102
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Melanoma is the most aggressive and dangerous skin cancer.
In 2013 about 23.8% of patients developed III–IV stages of a
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